Pure Global
NCT06332287

A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal Metastasis

A Prospective, Single-arm, and Exploratory Phase II Clinical Study of Trilaciclib Combined With Lateral Ventricular Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer With Leptomeningeal Metastasis
Jiangsu Province Nanjing Brain Hospital·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
NSCLC
Drug/Device/Intervention
combination of Trilaciclib and Pemetrexed
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Jiangsu Province Nanjing Brain Hospital
Location
Suzhou, China
Timeline & enrollment
Phase
Phase 2
Start date
May 01, 2023
End date
Jun 01, 2025
Enrollment
25 participants
Primary outcome

Duration of severe neutropenia (DSN)

Summary

To observe the efficacy of Trilaciclib combined with lateral ventricular chemotherapy in the
 treatment of non-small cell lung cancer with leptomeningeal metastasis。

Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06332287
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06332287 through Pure Global AI's free database. This Phase 2 trial is sponsored by Jiangsu Province Nanjing Brain Hospital and is currently Recruiting. The study focuses on NSCLC. Target enrollment is 25 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.